Atossa Genetics (NASDAQ:ATOS) Price Target Raised to $25.00

Atossa Genetics (NASDAQ:ATOS) had its price objective increased by stock analysts at HC Wainwright from $7.00 to $25.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 361.25% from the stock’s current price.

Several other equities research analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st. Ascendiant Capital Markets raised their price objective on Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $68.33.

Atossa Genetics Trading Down 1.6%

ATOS stock opened at $5.42 on Thursday. The company’s 50 day moving average is $5.88 and its 200 day moving average is $10.02. The stock has a market cap of $46.67 million, a price-to-earnings ratio of -1.51 and a beta of 1.42. Atossa Genetics has a 1-year low of $3.76 and a 1-year high of $19.35.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.29). As a group, sell-side analysts forecast that Atossa Genetics will post -0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Atossa Genetics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd boosted its stake in shares of Atossa Genetics by 581.2% during the fourth quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock valued at $100,000 after purchasing an additional 144,412 shares during the period. &PARTNERS bought a new position in shares of Atossa Genetics in the fourth quarter worth approximately $25,000. Graham Capital Management L.P. boosted its position in Atossa Genetics by 27.8% during the 4th quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock valued at $125,000 after buying an additional 45,923 shares during the period. State Street Corp increased its position in shares of Atossa Genetics by 31.2% in the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock valued at $352,000 after acquiring an additional 141,990 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Atossa Genetics by 33.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after acquiring an additional 514,175 shares during the last quarter. Institutional investors own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.